Đánh giá hiệu quả của hóa trị bổ trợ ECX trong ung thư dạ dày giai đoạn II-IV (MO)

Purpose: to evaluate the effecacy of adjuvant ECX regimen for patient after potentially curative resection of stomach cancer stage II-IV( Mo). Patients and Methods: 106 pts with stage II-IV (MO) treated with ECX. A pooled analysis for event-free (EFS) and overall survival (OS) using an estimated Kaplan-Meyer. Results: The minimum and the maximum follow-up duration was 7 months and 38 months. The 3 years EFS was 72.4 percent, as was 81.8 percent. Side-effect was leucopenia (32.1 percent), diarhea (11.5 percent), hand-foot syndrom (43.8 percent). Conclusion: ECX is tolerable and effective as standard adjuvant therapy for pts with stage II-IV (MO) stomach cancer.